PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
OLMA vs. DAC
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between OLMA and DAC is 0.12, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

OLMA vs. DAC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Olema Pharmaceuticals, Inc. (OLMA) and Danaos Corporation (DAC). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-62.74%
-8.53%
OLMA
DAC

Key characteristics

Sharpe Ratio

OLMA:

-0.63

DAC:

0.20

Sortino Ratio

OLMA:

-0.68

DAC:

0.46

Omega Ratio

OLMA:

0.92

DAC:

1.06

Calmar Ratio

OLMA:

-0.55

DAC:

0.06

Martin Ratio

OLMA:

-1.44

DAC:

0.46

Ulcer Index

OLMA:

34.51%

DAC:

10.65%

Daily Std Dev

OLMA:

79.46%

DAC:

24.10%

Max Drawdown

OLMA:

-96.26%

DAC:

-99.42%

Current Drawdown

OLMA:

-89.61%

DAC:

-81.19%

Fundamentals

Market Cap

OLMA:

$420.22M

DAC:

$1.50B

EPS

OLMA:

-$2.44

DAC:

$28.89

Total Revenue (TTM)

OLMA:

$0.00

DAC:

$751.40M

Gross Profit (TTM)

OLMA:

-$182.00K

DAC:

$500.14M

EBITDA (TTM)

OLMA:

-$105.21M

DAC:

$520.19M

Returns By Period

In the year-to-date period, OLMA achieves a -2.92% return, which is significantly higher than DAC's -3.26% return.


OLMA

YTD

-2.92%

1M

-7.21%

6M

-62.64%

1Y

-49.82%

5Y*

N/A

10Y*

N/A

DAC

YTD

-3.26%

1M

1.39%

6M

-8.45%

1Y

6.56%

5Y*

66.02%

10Y*

2.22%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

OLMA vs. DAC — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

OLMA
The Risk-Adjusted Performance Rank of OLMA is 1414
Overall Rank
The Sharpe Ratio Rank of OLMA is 1414
Sharpe Ratio Rank
The Sortino Ratio Rank of OLMA is 1616
Sortino Ratio Rank
The Omega Ratio Rank of OLMA is 1717
Omega Ratio Rank
The Calmar Ratio Rank of OLMA is 1414
Calmar Ratio Rank
The Martin Ratio Rank of OLMA is 77
Martin Ratio Rank

DAC
The Risk-Adjusted Performance Rank of DAC is 4848
Overall Rank
The Sharpe Ratio Rank of DAC is 5353
Sharpe Ratio Rank
The Sortino Ratio Rank of DAC is 4444
Sortino Ratio Rank
The Omega Ratio Rank of DAC is 4343
Omega Ratio Rank
The Calmar Ratio Rank of DAC is 4848
Calmar Ratio Rank
The Martin Ratio Rank of DAC is 5252
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

OLMA vs. DAC - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Olema Pharmaceuticals, Inc. (OLMA) and Danaos Corporation (DAC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for OLMA, currently valued at -0.63, compared to the broader market-2.000.002.004.00-0.630.20
The chart of Sortino ratio for OLMA, currently valued at -0.68, compared to the broader market-4.00-2.000.002.004.00-0.680.46
The chart of Omega ratio for OLMA, currently valued at 0.92, compared to the broader market0.501.001.502.000.921.06
The chart of Calmar ratio for OLMA, currently valued at -0.55, compared to the broader market0.002.004.006.00-0.550.17
The chart of Martin ratio for OLMA, currently valued at -1.44, compared to the broader market-10.000.0010.0020.0030.00-1.440.46
OLMA
DAC

The current OLMA Sharpe Ratio is -0.63, which is lower than the DAC Sharpe Ratio of 0.20. The chart below compares the historical Sharpe Ratios of OLMA and DAC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.50AugustSeptemberOctoberNovemberDecember2025
-0.63
0.20
OLMA
DAC

Dividends

OLMA vs. DAC - Dividend Comparison

OLMA has not paid dividends to shareholders, while DAC's dividend yield for the trailing twelve months is around 4.20%.


TTM2024202320222021
OLMA
Olema Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%
DAC
Danaos Corporation
4.20%4.06%4.12%5.70%2.01%

Drawdowns

OLMA vs. DAC - Drawdown Comparison

The maximum OLMA drawdown since its inception was -96.26%, roughly equal to the maximum DAC drawdown of -99.42%. Use the drawdown chart below to compare losses from any high point for OLMA and DAC. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-89.61%
-18.16%
OLMA
DAC

Volatility

OLMA vs. DAC - Volatility Comparison

Olema Pharmaceuticals, Inc. (OLMA) has a higher volatility of 27.83% compared to Danaos Corporation (DAC) at 7.92%. This indicates that OLMA's price experiences larger fluctuations and is considered to be riskier than DAC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%AugustSeptemberOctoberNovemberDecember2025
27.83%
7.92%
OLMA
DAC

Financials

OLMA vs. DAC - Financials Comparison

This section allows you to compare key financial metrics between Olema Pharmaceuticals, Inc. and Danaos Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab